Director, Senior Clinical and Scientific Expert Zoster Vaccines
GSK, Rockville, Maryland, United States
Dr. Peter Vink, a graduate of Grand Valley State Colleges (1971) and Wayne State University School of Medicine (1983), trained in Pediatrics at St. Luke's/Roosevelt Hospital Centers, NYC (1983-85) and Michigan State University Department of Pediatric and Human Development, Lansing (1985-86). His fellowship was in Immunology at UCLA Division of Immunology/Allergy/Cystic Fibrosis, Los Angeles (1987-1989).
From 1989-2002, he was an Assistant Professor in Allergy and Immunology, at University of Maryland Baltimore (UMB) Department of Pediatrics and Acting Chief of the Division of Immunology, Allergy and Rheumatology (1992-1995). While at UMB, he developed and directed the Pediatric AIDS Care and Evaluation Clinic (PACE) and Immunology Clinic at the University of Maryland Medical Systems, focusing on the prevention of maternal-infant perinatal HIV transmission and the effective use of active retroviral therapy in HIV-infected children. He was Principal Investigator from 1991-2002 for pediatric and perinatal HIV research through collaboration with the Pediatric AIDS Clinical Trial Group (PACTG), the CDC’s Pediatric AIDS Collaborative Transmission Study (PACTS) and the CDC’s PACTS-HIV Follow-up Perinatally Exposed Children (PACTS-HOPE). Additionally, he developed and built a BSL3 facility for pediatric HIV research and oversaw the UMB Pediatric Immunology research laboratory.
In 2002, he left academia becoming the Associate Director of Clinical Research for ID Biomedical Corporation where he worked on the development of a multi-valent Group A strep vaccine and a seasonal nasal influenza vaccine.
In 2005, with GSK’s purchase of ID Biomedical, he joined GSK Vaccines where he has participated to the development of early and next generation pneumococcal, NTHI, and COPD vaccines, investigated the clinical use of GSK’s Adjuvant Systems, and participated to the development and licensure of Nimerix and Shingrix vaccines.
He is currently the Senior Scientific and Clinical Expert for Zoster vaccines at GSK Vaccines. Since 2010, he has focused on the development of Shingrix, a non-live recombinant zoster subunit vaccine. His specific focus is in the development of Shingrix for the prevention of Herpes Zoster in immunocompromised, immunosuppressed and other patient populations were a live-virus zoster vaccine is contraindicated.
He has authored/co-authored 42 abstracts and 36 original manuscripts.
Additionallly, he is an avid traveler and collector of mid-century pottery.
Disclosure: GSK group of companies (Individual(s) Involved: Self): Employee, Shareholder